The Impact of Timeliness of Care on Survival in Non-small Cell Lung Cancer Patients

Introduction: It is uncertain whether timeliness improves clinical outcomes in lung cancer patients. The goal of the study was to analyse the influence of patient’s and doctor’s delays on survival of unselected population of NSCLC patients. Material and methods: From 1995 to 1998, 8705 squamous cell lung cancer patients and 1881 adenocarcinoma patients were registered in Pulmonary Outpatients Clinics in all parts of Poland and subsequently in National Tuberculosis and Lung Diseases Research Institute Register (NTLDRIR). Results: The median time from first symptom(s) to the beginning of a treatment was 92 days (mean—138.5 days).The median waiting time between first symptom(s) and first visit to a doctor’s was 30 days (mean 57 days) and from first visit to a doctor’s to referral to a chest physician—was 17 days (mean 41 days). Diagnosis of the NSCLC was established in a mean time of 71 days (median 40 days), but chest physician diagnosed patients in a mean time of 51 days (median 28 days). The multivariate analysis revealed that ECOG performance status (PS) 2 (HR = 1.4) and 3+4 (HR = 2.23), clinical stage of the disease II (HR = 1.32), III (HR = 1.41), and IV (HR = 1.82) were independent negative predictors of survival. Non-surgically treated patients had worse prognosis than patients treated surgically (HR = 3.03). Lack of patient’s delay had a significant positive impact on survival (HR = 0.88), particularly for patients in PS 0+1 (HR = 0.9) and 3+4 (HR = 0.9). Lack of doctor’s delay was a negative predictive factor of survival (HR = 1.14). It was observed particularly in patients in performance status 2 (HR = 1.28). Conclusions: The patient’s delay and lack of doctor’s delay had a negative impact on survival of NSCLC patients.